91 related articles for article (PubMed ID: 19800225)
41. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
42. New low-density lipoprotein receptor upregulators acting via a novel mechanism.
Ashton MJ; Brown TJ; Fenton G; Halley F; Harper MF; Lockey PM; Porter B; Roach AG; Stuttle KA; Vicker N; Walsh RJ
J Med Chem; 1996 Aug; 39(17):3343-56. PubMed ID: 8765518
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N
J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
[TBL] [Abstract][Full Text] [Related]
44. The association between insulin and low-density lipoprotein receptors.
Ramakrishnan G; Arjuman A; Suneja S; Das C; Chandra NC
Diab Vasc Dis Res; 2012 Jul; 9(3):196-204. PubMed ID: 22278734
[TBL] [Abstract][Full Text] [Related]
45. Nonsense-mediated decay of human LDL receptor mRNA.
Holla ØL; Kulseth MA; Berge KE; Leren TP; Ranheim T
Scand J Clin Lab Invest; 2009; 69(3):409-17. PubMed ID: 19148831
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones.
Kurogi Y; Inoue Y; Tsutsumi K; Nakamura S; Nagao K; Yoshitsugu H; Tsuda Y
J Med Chem; 1996 Mar; 39(7):1433-7. PubMed ID: 8691473
[TBL] [Abstract][Full Text] [Related]
47. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
48. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
Kong WJ; Vernieri C; Foiani M; Jiang JD
Pharmacol Ther; 2020 May; 209():107496. PubMed ID: 32001311
[TBL] [Abstract][Full Text] [Related]
49. Berberine-induced LDLR up-regulation involves JNK pathway.
Lee S; Lim HJ; Park JH; Lee KS; Jang Y; Park HY
Biochem Biophys Res Commun; 2007 Nov; 362(4):853-7. PubMed ID: 17767919
[TBL] [Abstract][Full Text] [Related]
50. The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms.
Abidi P; Chen W; Kraemer FB; Li H; Liu J
J Lipid Res; 2006 Oct; 47(10):2134-47. PubMed ID: 16885565
[TBL] [Abstract][Full Text] [Related]
51. Research progress on berberine with a special focus on its oral bioavailability.
Liu CS; Zheng YR; Zhang YF; Long XY
Fitoterapia; 2016 Mar; 109():274-82. PubMed ID: 26851175
[TBL] [Abstract][Full Text] [Related]
52. Insight on Structural Modification, Cytotoxic or Anti-Proliferative Activity, Structure-Activity Relationship of Berberine Derivatives.
Yin M; Mou J; Sun L; Deng Y; Ren X
Med Chem; 2023; 19(9):823-837. PubMed ID: 37016520
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of berberine as a natural fungicide: biodegradation and antimicrobial mechanism.
Li Y; Yin YM; Wang XY; Wu H; Ge XZ
J Asian Nat Prod Res; 2018 Feb; 20(2):148-162. PubMed ID: 28534425
[TBL] [Abstract][Full Text] [Related]
54. Predictive QSAR modeling study on berberine derivatives with hypolipidemic activity.
Yu P; Li D; Ni J; Zhao L; Ding G; Wang Z; Xiao W
Chem Biol Drug Des; 2018 Apr; 91(4):867-873. PubMed ID: 29143468
[TBL] [Abstract][Full Text] [Related]
55. A comprehensive account of insulin and LDL receptor activity over the years: A highlight on their signaling and functional role.
Chandra NC
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22840. PubMed ID: 34227185
[TBL] [Abstract][Full Text] [Related]
56. Discovery of seven-membered ring berberine analogues as highly potent and specific hCES2A inhibitors.
Yang Y; Xiong Y; Zhu G; Sun M; Zou K; Zhao Y; Zhang Y; Xu Z; Li Y; Zhu W; Jia Q; Li B; Ge G
Chem Biol Interact; 2023 Jun; 378():110501. PubMed ID: 37080375
[TBL] [Abstract][Full Text] [Related]
57. New Development of Novel Berberine Derivatives against Bacteria.
Jamshaid F; Dai J; Yang LX
Mini Rev Med Chem; 2020; 20(8):716-724. PubMed ID: 31902359
[TBL] [Abstract][Full Text] [Related]
58. Discovery of 7,9-Disulfatetrahydroberberine as Novel Lipid-Lowering Agents.
Li DD; Yu P; Wang ZZ; Xiao W; Zhou XH; Zhao LG
ACS Omega; 2020 Dec; 5(48):30836-30848. PubMed ID: 33324793
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and antioxidant activities of berberine 9-
Liu Y; Long S; Zhang S; Tan Y; Wang T; Wu Y; Jiang T; Liu X; Peng D; Liu Z
RSC Adv; 2021 May; 11(29):17611-17621. PubMed ID: 35480221
[TBL] [Abstract][Full Text] [Related]
60. The basal SAR of a novel insulin receptor activator.
Wood HB; Black R; Salituro G; Szalkowski D; Li Z; Zhang Y; Moller DE; Zhang B; Jones AB
Bioorg Med Chem Lett; 2000 Jun; 10(11):1189-92. PubMed ID: 10866378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
